首页> 外文期刊>Transplantation Proceedings >Use of genetically modified allograft to deliver local immunomodulatory molecule with minimal systemic toxicity in a rat model of allogeneic skin flap transplantation.
【24h】

Use of genetically modified allograft to deliver local immunomodulatory molecule with minimal systemic toxicity in a rat model of allogeneic skin flap transplantation.

机译:在同种异体皮瓣移植的大鼠模型中,使用基因修饰的同种异体移植物以最小的全身毒性递送局部免疫调节分子。

获取原文
获取原文并翻译 | 示例
           

摘要

The effects of OX40-OX40 ligand (OX40L) costimulatory pathway blockade to prevent T-cell-mediated acute rejection were investigated in a rat model of allogeneic superficial inferior epigastric artery flap transplantation. An ex vivo gene transfer technique was used to modify allografts to locally deliver an immunomodulatory molecule. The flaps were separated from donors, perfused with an adenoviral vector expressing the OX40 immunoglobulin (AdOX40Ig) for 1 hour, and incubated at 37 degrees C for 2 hours. Before transplantation, the flaps were flushed with phosphate-buffered saline solution to remove unincorporated viral particles. Recipients were randomly divided into 5 groups, and treated with topical OX40Ig gene transfer, a single low dose of rapamycin alone, or a combination of agents. Graft survival was assessed using histopathologic classification of skin rejection. All animals in the untreated group (n = 9) or the group treated with adenovirus expressing green fluorescence protein (n = 9) developed grade 3 clinical rejection by postoperative day 7. No significant difference was observed in graft survival between the locally treated AdOX40Ig groups (mean [SD], 8.1 [0.7] days) and the untreated groups (7.7 [1.2] days) could be observed (P > .05, t test). Graft survival in the locally treated AdOX40Ig groups was extended to 18.7 (1.2) days when transduction was combined with a low dose of rapamycin, a significant improvement over survival with rapamycin treatment alone (13.2 [0.6] days) (P < .01). These results demonstrated that local immunomodulation by the allograft itself and low-dose rapamycin treatment promote graft acceptance. This protocol may enable reduction of the dosage of immunosuppressive drugs needed for successful inhibition of acute rejection in the early postoperative period.
机译:在同种异体浅表下腹肌动脉皮瓣移植的大鼠模型中研究了OX40-OX40配体(OX40L)共刺激途径的阻断对预防T细胞介导的急性排斥反应的影响。使用离体基因转移技术修饰同种异体移植物以局部递送免疫调节分子。将皮瓣与供体分开,用表达OX40免疫球蛋白的腺病毒载体(AdOX40Ig)灌注1小时,并在37℃下孵育2小时。移植前,皮瓣用磷酸盐缓冲盐溶液冲洗,以去除未结合的病毒颗粒。将接受者随机分为5组,并分别接受局部OX40Ig基因转移,单次低剂量雷帕霉素或多种药物联合治疗。使用皮肤排斥的组织病理学分类评估移植物存活。术后第7天,未治疗组(n = 9)或用表达绿色荧光蛋白的腺病毒治疗组(n = 9)中的所有动物均发展为3级临床排斥反应。在局部治疗的AdOX40Ig组之间,未观察到移植物存活率的显着差异(平均[SD],8.1 [0.7]天)和未治疗组(7.7 [1.2]天)可以观察到(P> 0.05,t检验)。当转导与低剂量雷帕霉素联合使用时,局部治疗的AdOX40Ig组的移植物存活时间延长至18.7(1.2)天,比单独雷帕霉素治疗的存活时间(13.2 [0.6]天)有显着改善(P <.01)。这些结果表明,同种异体移植物自身的局部免疫调节和低剂量雷帕霉素治疗促进了移植物的接受。该方案可以减少在术后早期成功抑制急性排斥反应所需的免疫抑制药物的剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号